Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HROW | Common Stock | Sale | -$129K | -14.2K | -15.73% | $9.09 | 75.8K | Sep 15, 2021 | See Footnote | F1, F2, F3 |
transaction | HROW | Common Stock | Sale | -$52.7K | -5.84K | -7.7% | $9.02 | 70K | Sep 16, 2021 | See Footnote | F1, F3, F4 |
holding | HROW | Common Stock | 100K | Sep 15, 2021 | Direct |
Id | Content |
---|---|
F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021. |
F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $9.28, inclusive. The reporting person undertakes to provide to Harrow Health, Inc. ("Harrow"), any security holder of Harrow, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
F3 | Represents shares held by the Lindstrom Family Limited Partnership No. 2, a limited partnership of which the reporting person is the general partner. |
F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.10, inclusive. The reporting person undertakes to provide to Harrow, any security holder of Harrow, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |